The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)

This study is setting up a special database, called a registry, specifically for people who have been diagnosed with a very rare type of cancer known as Epithelioid Hemangioendothelioma, or EHE. EHE is a kind of sarcoma, which is a cancer that starts in soft tissues like muscle, fat, or blood vessels. Because EHE is so rare, affecting only a tiny number of people each year, doctors and researchers still have a lot to learn about it. They don't fully understand how it progresses, why it acts differently in various people, or what the very best treatments are.

The main goal of this registry is to collect detailed معلومات (information) from adult patients who are newly diagnosed with EHE. By carefully tracking their journey – details about their diagnosis, their treatment choices, and how their disease progresses over time – doctors hope to build a much clearer picture of EHE. This will help them to better understand the disease's natural course, identify what factors might predict how someone will respond to treatment, and see which treatments are most effective in real-world settings. Ultimately, all this information aims to improve how EHE is managed and treated in the future.

This registry is a big collaborative effort, involving many cancer centres across the EU and UK that specialise in EHE. Patients are being enrolled from December 2023, and the study plans to continue collecting data for about ten years. It's important to know that this registry is supported by several organisations, including EHE Rare Cancer Charity UK, showing a strong commitment to improving understanding and care for people with this rare condition.